Ginkgo Bioworks Holdings, Inc. Stock Research

Market Summary

USD1.33+0.10

Market Closed

8.13%

DNA Alerts

3 major insider sales recently.
Big fall in Revenue (Y/Y)
Big jump in Earnings (Y/Y)
Losses in recent quarter

DNA Stock Price

DNA RSI Chart

DNA Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-1.03

Price/Sales (Trailing)

4.54

EV/EBITDA

-0.41

Price/Free Cashflow

-7.12

DNA Price/Sales (Trailing)

DNA Profitability

EBT Margin

-670.21%

Return on Equity

-245.97%

Return on Assets

-188.65%

Free Cashflow Yield

-14.04%

DNA Fundamentals

DNA Revenue

Revenue (TTM)

477.7M

Revenue Y/Y

-33.81%

Revenue Q/Q

48.02%

DNA Earnings

Earnings (TTM)

-2.1B

Earnings Y/Y

88.97%

Earnings Q/Q

73.61%

Price Action

52 Week Range

1.174.91

(Low)(High)

Last 7 days

4.7%

Last 30 days

-5%

Last 90 days

-21.3%

Trailing 12 Months

-67%

DNA Financial Health

Current Ratio

11.71

DNA Investor Care

Shares Dilution (1Y)

23.22%

Diluted EPS (TTM)

-1.25

Financials for Ginkgo Bioworks Holdings

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-9.5%	477,706,000	527,915,000	539,127,000	438,145,000	313,837,000
Operating Expenses	-35.8%	2,686,658,000	4,187,094,000	3,571,957,000	2,884,012,000	2,142,304,000
S&GA Expenses	-35.2%	1,429,799,000	2,206,982,667	1,665,349,333	862,952,000	-
R&D Expenses	-43.3%	1,052,643,000	1,856,513,000	1,649,954,000	1,412,797,000	1,149,662,000
EBITDA	-15.1%	-3,490,597,000	-3,033,922,000	-2,220,765,145	-1,818,701,000	-
EBITDA Margin	-17.5%	-6.61	-5.63	-5.07	-5.80	-
Earnings Before Taxes	40.0%	-2,121,399,000	-3,538,153,000	-2,971,682,000	-2,355,962,000	-1,838,122,000
EBT Margin	-21.6%	-6.70	-5.51	-5.50	-5.86	-
Interest Expenses	137.9%	10,951,000	4,603,000	2,451,000	2,373,000	-
Net Income	40.4%	-2,104,929,000	-3,529,041,000	-2,961,867,000	-2,346,983,000	-1,830,047,000
Net Income Margin	-21.7%	-6.68	-5.49	-5.48	-5.83	-
Free Cahsflow	-9.9%	-344,778,000	-313,676,000	-311,411,562	-310,339,000	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	35.7%	2,539	1,871	1,994	2,058	2,071
Current Assets	-0.8%	1,450	1,462	1,599	1,706	1,723
Cash Equivalents	1.0%	1,316	1,303	1,377	1,493	1,550
Inventory	-25.5%	4.00	6.00	8.00	9.00	3.00
Net PPE	67.8%	315	188	176	149	146
Goodwill	109.0%	60.00	29.00	31.00	21.00	21.00
Liabilities	86.3%	803	431	427	444	504
Current Liabilities	38.6%	173	125	135	159	135
Shareholder's Equity	21.0%	1,736	1,435	1,567	1,614	1,505
Retained Earnings	-4.1%	-4,397	-4,226	-3,557	-2,888	-2,297
Additional Paid-In Capital	8.2%	6,136	5,669	5,098	4,471	3,805
Accumulated Depreciation	6.7%	83.00	78.00	70.00	61.00	-
Shares Outstanding	-0.3%	1,631	1,636	1,607	1,611	-
Minority Interest	-100.0%	-	5.00	32.00	33.00	62.00

* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	19.4%	-252	-313	-289	-225	-253
Share Based Compensation	-43.4%	1,931	3,414	2,851	2,259	1,606
Cashflow From Investing	27.5%	-67.39	-92.91	-76.93	-86.20	-73.26
Cashflow From Financing	799.0%	95.00	-13.64	1,535	1,533	1,534
Buy Backs	NaN%	0.00	0.00	25.00	-	-

Risks for DNA

What is the probability of a big loss on DNA?

68.6%

Probability that Ginkgo Bioworks Holdings stock will be more than 20% underwater in next one year

68.6%

Probability that Ginkgo Bioworks Holdings stock will be more than 30% underwater in next one year.

64.7%

Probability that Ginkgo Bioworks Holdings stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does DNA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Ginkgo Bioworks Holdings was unfortunately bought at previous high price.

Drawdowns

Returns for DNA

Cumulative Returns on DNA

Which funds bought or sold DNA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-23	MetLife Investment Management, LLC	added	3.76	-32,456	41,653	-%
2023-03-17	American Portfolios Advisors	added	6.29	61,926	219,358	0.01%
2023-03-15	B. Riley Wealth Advisors, Inc.	new	-	118,109	118,109	-%
2023-03-13	Claro Advisors LLC	sold off	-100	-238,000	-	-%
2023-03-10	BAILLIE GIFFORD & CO	added	19.65	-224,061,000	412,659,000	0.43%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	added	23.12	-92,526	184,474	-%
2023-03-08	Capital Asset Advisory Services LLC	unchanged	-	-61,175	71,825	0.01%
2023-03-06	OLD MISSION CAPITAL LLC	new	-	10,962	10,962	-%
2023-03-06	Rockefeller Capital Management L.P.	reduced	-12.13	-3,000	1,000	-%
2023-03-06	NORTH STAR ASSET MANAGEMENT INC	added	42.97	-18,146	61,854	-%

Latest Funds Activity

Are funds buying DNA calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own DNA

No. of Funds

Ginkgo Bioworks Holdings News

Schedule 13G FIlings of Ginkgo Bioworks Holdings

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	che austin	6.3%	99,857,282	SC 13G/A
Feb 14, 2023	knight thomas f. jr.	5.0%	74,936,116	SC 13G/A
Feb 14, 2023	anchorage capital group, l.l.c.	4.83%	69,904,593	SC 13G/A
Feb 14, 2023	viking global investors lp	9.36%	143,085,126	SC 13G/A
Feb 13, 2023	general atlantic, l.p.	2.4%	32,319,896	SC 13G/A
Feb 09, 2023	vanguard group inc	7.49%	101,521,280	SC 13G
Jan 25, 2023	shetty reshma p.	12.0%	195,788,523	SC 13D/A
Jan 25, 2023	kelly jason r	6.2%	97,017,435	SC 13D/A
Jan 23, 2023	baillie gifford & co	18.03%	244,176,643	SC 13G/A
Jul 01, 2022	viking global investors lp	9.7%	115,084,128	SC 13G

DNA Fair Value

Recent SEC filings of Ginkgo Bioworks Holdings

View All Filings

Date Filed	Form Type	Document
Mar 31, 2023	4	Insider Trading
Mar 31, 2023	4	Insider Trading
Mar 31, 2023	4	Insider Trading
Mar 30, 2023	144	Notice of Insider Sale Intent
Mar 30, 2023	144	Notice of Insider Sale Intent
Mar 29, 2023	144	Notice of Insider Sale Intent
Mar 29, 2023	144	Notice of Insider Sale Intent
Mar 24, 2023	4	Insider Trading
Mar 24, 2023	4	Insider Trading
Mar 24, 2023	4	Insider Trading

Latest Insider Trading transactions for DNA

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-23	Shetty Reshma P.	sold	-47,363	1.258	-37,650	see remarks
2023-03-23	Canton Barry	sold	-47,363	1.258	-37,650	-
2023-03-23	Kelly Jason R	sold	-125,800	1.258	-100,000	see remarks
2023-03-22	Shetty Reshma P.	sold	-48,530	1.289	-37,650	see remarks
2023-03-22	Canton Barry	sold	-48,530	1.289	-37,650	-
2023-03-22	Kelly Jason R	sold	-128,500	1.285	-100,000	see remarks
2023-03-16	Kelly Jason R	sold	-131,500	1.315	-100,000	see remarks
2023-03-16	Canton Barry	sold	-49,509	1.315	-37,650	-
2023-03-16	Shetty Reshma P.	sold	-49,509	1.315	-37,650	see remarks
2023-03-15	Kelly Jason R	sold	-131,700	1.317	-100,000	see remarks

About Ginkgo Bioworks Holdings

Jason Kelly

www.ginkgobioworks.com

640

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

DNA Income Statement

2022-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Biosecurity revenue:

Total revenue

$ 477,706

$ 313,837

$ 76,657

Costs and operating expenses:

Research and development

1,052,643

1,149,662

159,767

General and administrative expenses

1,429,799

862,952

38,306

Total operating expenses

2,686,658

2,142,304

213,684

Loss from operations

(2,208,952)

(1,828,467)

(137,027)

Other income (expense):

Interest income

20,262

837

2,582

Interest expense

(106)

(2,373)

(2,385)

(Loss) gain on equity method investments:

(43,761)

(77,284)

(396)

Loss on investments

(53,335)

(11,543)

(3,733)

Change in fair value of warrant liabilities

124,970

58,615

Gain on settlement of partnership agreement

23,826

8,286

Gain on deconsolidation of subsidiaries

31,889

Other income (expense), net

7,634

(1,733)

7,839

Total other income (expense), net

87,553

(9,655)

12,193

Loss before income taxes

(2,121,399)

(1,838,122)

(124,834)

Income tax (benefit) provision

(15,027)

(1,480)

1,889

Net loss

(2,106,372)

(1,836,642)

(126,723)

Loss attributable to non-controlling interest

(1,443)

(6,595)

(114)

Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders

$ (2,104,929)

$ (1,830,047)

$ (126,609)

Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders (2):

Basic

$ (1.25)

$ (1.35)

$ (0.10)

Diluted

$ (1.25)

$ (1.39)

$ (0.10)

Weighted average common shares outstanding (2)

Basic

1,679,061,465

1,359,848,803

1,274,766,915

Diluted

1,679,838,849

1,360,373,343

1,274,766,915

Comprehensive loss:

Net loss

$ (2,106,372)

$ (1,836,642)

$ (126,723)

Other comprehensive loss:

Foreign currency translation adjustment

(917)

(1,715)

Total other comprehensive loss

(917)

(1,715)

Comprehensive loss

(2,107,289)

(1,838,357)

(126,723)

Product

Biosecurity revenue:

Total revenue

35,455

23,040

8,707

Costs and operating expenses:

Cost of Biosecurity revenue

20,646

20,017

6,705

Service

Biosecurity revenue:

Total revenue

298,585

177,808

8,729

Costs and operating expenses:

Cost of Biosecurity revenue

183,570

109,673

8,906

Foundry Revenue [Member]

Biosecurity revenue:

Total revenue

^[1]

$ 143,666

$ 112,989

$ 59,221

[1]

(1)
(2)

Includes related party revenue of $38,813, $47,161, and $42,535 for the years ended 2022, 2021, and 2020, respectively.
Amounts for the year ended December 31, 2020 have been retroactively restated for the reverse recapitalization as described in Note 2.

DNA Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,315,792	$ 1,550,004
Accounts receivable, net	80,907	131,544
Accounts receivable - related parties	1,558	4,598
Inventory, net	4,364	3,362
Prepaid expenses and other current assets	47,458	33,537
Total current assets	1,450,079	1,723,045
Property, plant, and equipment, net	314,773	145,770
Operating lease right-of-use assets	400,762	0
Investments	112,188	102,037
Equity method investments	1,543	13,194
Intangible assets, net	111,041	21,642
Goodwill	60,210	21,312
Other non-current assets	88,725	43,990
Total assets	2,539,321	2,070,990
Current liabilities:
Accounts payable	10,451	8,189
Deferred revenue (includes $10,309 and $12,502 from related parties)	47,817	33,240
Accrued expenses and other current liabilities	114,694	93,332
Total current liabilities	172,962	134,761
Non-current liabilities:
Deferred rent, net of current portion	0	18,746
Deferred revenue, net of current portion (includes $131,188 and $148,319 from related parties)	174,767	155,991
Operating lease liabilities, non-current	413,256	0
Lease financing obligation		22,283
Warrant liabilities	10,868	135,838
Other non-current liabilities	31,191	35,992
Total liabilities	803,044	503,611
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued	0	0
Common stock $0.0001 par value (Note 12)	190	161
Additional paid-in capital	6,136,378	3,804,844
Accumulated deficit	(4,397,659)	(2,297,925)
Accumulated other comprehensive loss	(2,632)	(1,715)
Total Ginkgo Bioworks Holdings, Inc. stockholders’ equity	1,736,277	1,505,365
Non-controlling interest	0	62,014
Total stockholders’ equity	1,736,277	1,567,379
Total liabilities and stockholders’ equity	$ 2,539,321	$ 2,070,990